Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Monoclonal Antibody

Anti-Clostridium Difficile Toxin B/tcdB Monoclonal Antibody (1A254)

Catalog #:   MXX00303 Specific References (49) DATASHEET
Host species: Mouse
Isotype: IgG
Applications: GICA, IFA
Overview

Catalog No.

MXX00303

Species reactivity

Clostridioides difficile (Peptoclostridium difficile)

Host species

Mouse

Isotype

IgG

Clonality

Monoclonal

Immunogen

Clostridium Difficile Toxin B/tcdB Protein.

Target

Toxin B, 3.4.22.-, Glucosyltransferase TcdB, 2.4.1.-, tcdB, toxB

Concentration

1mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

GICA, IFA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

1A254

Data Image
References

IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity., PMID:40048372

Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study., PMID:39447053

Development of two recombinant vaccines against Clostridioides difficile infection and immunogenicity in pregnant sows and neonatal piglets., PMID:39127403

Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile., PMID:38923049

A sequence invariable region in TcdB2 is required for toxin escape from Clostridioides difficile., PMID:38888328

Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism., PMID:38761377

Atomically accurate de novo design of antibodies with RFdiffusion., PMID:38562682

The impact of existing total anti-toxin B IgG immunity in outcomes of recurrent Clostridioides difficile infection., PMID:38552897

Establishment of a Novel Detection Platform for Clostridioides difficile Toxin Genes Based on Orthogonal CRISPR., PMID:37378559

Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B., PMID:35469152

Gastrobodies are engineered antibody mimetics resilient to pepsin and hydrochloric acid., PMID:34381153

Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection., PMID:34145250

Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Enhances Adaptive Immunity to C difficile Toxin B., PMID:33444574

Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B., PMID:33370413

Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum., PMID:33164145

Rapid and fully-automated detection of Clostridium difficile Toxin B via magnetic-particle-based chemiluminescent immunoassay., PMID:32913500

Human C. difficile toxin-specific memory B cell repertoires encode poorly neutralizing antibodies., PMID:32663199

Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials., PMID:32504314

Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment., PMID:32376702

Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value., PMID:31733265

Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027., PMID:31578248

Assessment of Bezlotoxumab Immunogenicity., PMID:31411386

Structure of the full-length Clostridium difficile toxin B., PMID:31308519

Rapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy., PMID:31279995

Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B., PMID:31233493

Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge., PMID:31138615

Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model., PMID:30736358

Neutralization of Clostridium difficile toxin B with VHH-Fc fusions targeting the delivery and CROPs domains., PMID:30540857

Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection., PMID:29788418

Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting., PMID:29632249

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence., PMID:29538686

Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?, PMID:29534621

Bezlotoxumab for the Prevention of Clostridium difficile Recurrence., PMID:29409575

Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy., PMID:29272036

Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence., PMID:28865041

Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants., PMID:28842504

Bezlotoxumab for the prevention of Clostridium difficile recurrence., PMID:28805081

Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection., PMID:28730660

Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection., PMID:28636484

Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?, PMID:28480750

Bezlotoxumab: First Global Approval., PMID:27905086

Colon-Targeted Delivery of IgY Against Clostridium difficile Toxin A and B by Encapsulation in Chitosan-Ca Pectinate Microbeads., PMID:27826799

A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile., PMID:27770789

Coordination between T helper cells, iNKT cells, and their follicular helper subsets in the humoral immune response against Clostridium difficile toxin B., PMID:27566831

Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin., PMID:27527088

Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection., PMID:27502696

A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection., PMID:27413067

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence., PMID:27365387

Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model., PMID:27336843

Datasheet
$ 196
Product specifications
50 μg 196 100 μg 313

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Clostridium Difficile Toxin B/tcdB Monoclonal Antibody (1A254) [MXX00303]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only